Market Cap (In USD)
2182.00
Revenue (In USD)
14.23 Million
Net Income (In USD)
-7.6 Million
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.0E-4-1.0E-4
- PE
- -
- EPS
- -
- Beta Value
- -80.287
- ISIN
- US9172731047
- CUSIP
- 917273104
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bryon Merade
- Employee Count
- -
- Website
- https://www.urologix.com
- Ipo Date
- 1996-05-30
- Details
- Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.
More Stocks
-
CORE-B
-
GVFG
-
POLSONPolson Limited
POLSON
-
ISHITADRIshita Drugs and Industries Limited
ISHITADR
-
HENGF
-
6933
-
WWPW
-
CALZFPolyNovo Limited
CALZF